Increased Risk of Cardiovascular Death in Breast Cancer Patients Without Chemotherapy or (and) Radiotherapy: A Large Population-Based Study

Tianwang Guan[1,2,3†], Hanbin Zhang[2,4†], Jinming Yang[2,4†], Wenrui Lin[2,4], Kenie Wang[5], Miao Su[2,4], Weien Peng[4], Yemin Li[4], Yanxian Lai[1,2] and Cheng Liu[1,2*]

[1] Department of Cardiology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China, [2] Department of Cardiology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China, [3] Department of Cardiology, Laboratory of Heart Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China, [4] Department of Clinical Medicine, Clinical Medical School, Guangzhou Medical University, Guangzhou, China, [5] The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

Background: Cardiovascular death (CVD) in breast cancer patients without chemotherapy (CT) or (and) radiotherapy (RT) has not been studied yet. This study evaluates the correlation between breast cancer and CVD risk independent of chemotherapy or (and) radiotherapy.

Methods: Data of female breast cancer patients without receiving CT or RT were retrieved from the Surveillance, Epidemiology, and End Result (SEER) database (2004–2015). Data were divided into two cohorts: tumor resection cohort and no resection cohort. The CVD risk in patients was expressed as standardized mortality ratios (SMRs). A 1:1 propensity score matching (PSM) was applied to balance inter-group bias, and competing risk regressions were utilized to evaluate the impact of tumor resection on CVD.

Results: The CVD risk was significantly higher (SMR = 2.196, 95% CI: 2.148–2.245, $P<0.001$) in breast cancer patients who did not receive CT or RT compared to the general population. Breast cancer patients without tumor resection showed higher CVD risk than patients who underwent tumour resection (tumor resection SMR = 2.031, 95% CI: 1.983–2.079, $P<0.001$; no resection SMR = 5.425, 95% CI: 5.087–5.781, $P<0.001$). After PSM, the CVD risk among patients without tumor resection indicated an increase of 1.165-fold compared to patients with tumor resection (HR=1.165, 95% CI: 1.039–1.306, $P=0.009$).

Conclusions: Female breast cancer patients are at higher risk of CVD despite unexposure to cardio-toxic CT or RT. However, female breast cancer patients subjected to tumor resection have decreased CVD risk. These results indicated that

monitoring female breast cancer patients not receiving RT or CT might serve as a preventative measure against CVD.

Keywords: breast cancer, cardiovascular death, chemotherapy, radiotherapy, cardio-oncology

INTRODUCTION

Breast cancer is a serious common threat for women's health, accounting for 30% of new cancer cases in females, and is on a growing trend (1, 2). Rapid advances in cancer screening and treatment technologies increased the five-year survival rate to 90% (1). By 2014, the estimated number of breast cancer survivors has reached over 3.1 million in the United States and is anticipated to rise to more than 3.9 million by 2024 (3). However, cardiovascular diseases appear to be a life-threatening complication for the survivors. Cardiovascular death (CVD) is becoming the leading cause of death in breast cancer survivors (4, 5). Identifying the population at high risk of CVD is a key step in implementing routine preventative measures to improve breast cancer survivors' prognosis.

At the present, the mainstream belief among cardio-oncologists is that cardiotoxic therapies, including chemotherapy (CT) or radiotherapy (RT), are the main contributors to increase CVD risk in breast cancer survivors (6, 7). The clinical guideline of American Society of Clinical Oncology (ASCO) (8) limits the target population needing prevention and monitoring of cardiac dysfunction to those who have accepted cardiotoxic therapies. However, the target population mentioned in ASCO is restricted, and the guideline might neglect CVD risk among cancer patients who opted out of cardiotoxic therapies.

Previous studies indicated that CVD risk might also be higher among breast cancer patients not exposed to CT or RT. A recent study revealed that breast cancer survivors suffered elevated CVD risk (9). Furthermore, a population-based study also showed that CVD risk of breast cancer survivors was apparently higher than that of the general population (10). These two studies evaluated CVD risk in breast cancer survivors regardless of the treatment regimen (with or without CT/RT). Surprisingly, another study reported no increase in CVD risk among breast cancer survivors pretreated with CT/RT compared to the general population (11). These results suggested that elevated CVD risk among breast cancer survivors was resulting in part from those not exposed to CT or RT. A single-center study supported this possibility and found decreased cardiac function among cancer patients not exposed to CT or RT (12). Another study also revealed that tumors could directly induce cardiovascular damage by tumor-induced inflammation in tumor-bearing mice (13). The cardiotoxicity of CT and RT in breast cancer patients is confirmed, but it remains elusive whether avoiding CT and/or RT regimens lower or increase CVD risk in breast cancer survivors. This calls for urgent need to evaluate, by large-scale population-based study, the CVD risk among breast cancer patients who opted out of the CT and/or RT treatments.

On the molecular level, breast cancer is a heterogeneous disease and the treatment selections for breast cancer patients are affected by the molecular subtypes, especially CT and hormonal therapy (14). Breast cancer patients who received neither CT nor RT may receive hormonal treatments. Hormonal treatments in breast cancer mainly include selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and ovarian suppression, and their cardiovascular effects are heterogeneity. Firstly, tamoxifen and other SERMs increase the risk of venous thromboembolism, but improve the outcomes of atherothrombosis related cardiovascular events in patients with breast cancer (15–18). Secondly, AIs are associated with increased risks of CVD and low-density lipoprotein cholesterol serum levels compared to tamoxifen (19, 20). However, more studies on AIs showed that AIs are related to higher risks of cardiovascular events compared to tamoxifen, possibly due to tamoxifen related cardioprotective effects, and AIs themselves may have no effects on cardiovascular events and cholesterol levels compared to placebo or no treatment (16–18). Thirdly, there is no evidence that ovarian suppression has cardiovascular specific side effects in breast cancer patients (21). These results suggested that hormonal treatments might add minor effect (possibly no effects or cardioprotective effects) on CVD risk in breast cancer patients who received neither CT nor RT.

This study evaluates the CVD risk among breast cancer patients who opted out of the CT or (and) RT, no matter they received hormonal treatments or not. The analysis aims to achieve three objectives. Objective 1 is to evaluate CVD risk of breast cancer patients who never received CT or RT in comparison to the general population. Objective 2 is to evaluate CVD risk of breast cancer patients who never received CT or RT and were either subjected or not to tumor resection in comparison to the general population. Objective 3 is to conduct internal comparisons among breast cancer patients, aiming to reduce treatment selection bias and evaluate the independent effect of tumor removal on the CVD risk in breast cancer patients who never received CT or RT. The study aims at updating the guidelines of which breast cancer population requires prevention and monitoring for CVD risk.

PATIENTS AND METHODS

Data Source

In this registry-based cohort study, the data of breast cancer patients were obtained from the Surveillance, Epidemiology, and

---

Abbreviations: AIs, aromatase inhibitors; CIs, confidence intervals; CT, Chemotherapy; CVD, Cardiovascular death; ER, Estrogen receptor; HER2, Human epidermal receptor 2; PR, Progesterone receptor; PSM, Propensity score matching; RT, Radiotherapy; SEER, Surveillance, Epidemiology, and End Result database; SMR, Standardized mortality ratio; SERMs, Selective estrogen receptor modulators.

End Result database (SEER) database, an authoritative program providing data of 18 cancer registries and covering approximately 34.6% of the American population (http://seer.cancer.gov/). The SEER database has been frequently used for cardio-oncology studies (9, 10, 22, 23). To compare with the cohort derived from the SEER database, the referred standardized population cohort was retrieved from Wide-ranging Online Data for Epidemiologic Research of the Centers for Disease Control and Prevention (CDC WONDER). CDC WONDER shares data of the general American population, which is based on death certificates of American residents. Ethical approval of this publicly available information was not required (9).

Study Population and Design
Only the female breast cancer patients without evidence for chemotherapy (CT) or radiotherapy (RT) were included in this study. Targeted therapy is classified as one kind of CT in the SEER database. The inclusion criteria were as follows: (1) case selection (site and morphology, primary site-labeled) = "C50.x"; (2) pathological diagnosis between 2004 and 2015; (3) patients with

only one primary tumor; (4) patients with active follow-up. The exclusion criteria were as follows: (1) history of CT or RT; (2) unknown causes of deaths; (3) male patients; (4) age at diagnosis under 45 years old; (5) unknown stage according to the American Joint Committee on Cancer (AJCC) staging system; (6) unknown surgery. Patients under 45 years old were excluded due to their very low numbers (**Figure 1**) (22). After the inclusion and the exclusion criteria, we established an overall cohort.

Firstly, for Objective 1, CVD risk in 10-year age-stratum (45-54, 55-64, 65-74, 75-84, ≥85) of the overall cohort was compared to that of the age-matched U.S. female population, which was expressed as standardized mortality ratio (SMR). Secondly, for Objective 2, the overall cohort was categorized into two cohorts according to surgical resection: tumor resection cohort and no resection cohort. We compared the CVD risk between the tumor resection cohort and the no resection cohort by using SMR. Thirdly, for Objective 3, participants were further excluded from the overall patients if they had unknown or unspecific information regarding their marital status, race, grade, estrogen receptor (ER) status, and progesterone receptor (PR) status. Patients with paired tumor site or unspecific tumor site were also excluded owing to

FIGURE 1 | Selection of eligible patients and study design. CVD, cardiovascular death; SMR, standardized mortality ratio.

their very low number. Then resection selection cohort was extracted and further divided into two sub-cohorts: tumor resection sub-cohort and no resection sub-cohort (**Figure 1**).

Participant Variables and Outcomes

Patient variables included surgery (tumor resection and no resection), age at diagnosis (45-60 years, >60 years), race (white, non-white), marital status (married, unmarried), laterality (left, right), grade (high, low), ER status (positive, negative), PR status (positive, negative), human epidermal receptor 2 (HER2) status (positive, negative, unknown), and AJCC stage (I, II, III, and IV) (4).

We classified causes of death as CVD or non-CVD. The CVD was defined as deaths due to heart disease (I00-I09, I11, I13, I20-I51), hypertension without heart disease (I10, I12), cerebrovascular disease (I60-I69), atherosclerosis (I70), aortic aneurysm and dissection (I71) and other diseases of arteries, arterioles and capillaries (I72-I78), according to the International Classification of Disease-10 (ICD-10) codes (22, 23). The non-CVD contained patients died from other causes and were considered as the competing events against CVD. Patients who survived till the last follow-up were treated as censored observations. The follow-up period was calculated as the time from the date of first diagnosis with breast cancer to the date of death or last follow-up. The final follow-up date was on December 31, 2015.

Statistical Analysis

Chi-square test was used to evaluate categorical variables in baseline characteristics. SMR was defined as the ratio of the observed deaths to the expected (24). The expected number of deaths was calculated according to the following formula: expected deaths = person-years × mortality rate of CVD among general population, where the mortality rate of CVDs is available on CDC WONDER (23), and the person-years is the sum of patients' survival time, from the date of breast cancer diagnosis to the date of study completion or the date of CVD. Ninety-five percent confidence intervals (95% CIs) and P value of SMRs were calculated by using the methods by Rothman-Boice (24) and by Altman et al. (25), respectively.

To reduce potential imbalance between breast patients who received tumor resection and no resection, a 1:1 propensity score matching (PSM) was applied. The PSM was performed using logistic regression and nearest neighbor method with caliper width of 0.01. PSM should match the confounding variables instead of all baseline variables (26). The potential confounding variables used for matching included age at diagnosis, marital status, grade, ER status, PR status, HER2 status, and AJCC stage. The balances between matched covariates were acceptable if P values were greater than 0.05 (27).

Further, the univariate and multivariate Fine and Gray's competing risks regressions were used to evaluate the independent effect of tumor resection on the CVD risk among breast cancer patients without CT or RT. The Fine and Gray's competing risks regression was performed to account for the two competing events: CVD deaths and non-CVD deaths.

Chi-square test and PSM were analyzed using SPSS version 25.0 (SPSS, Chicago, IL) and R software version 3.6.1 (https://www.r-project.org), respectively. Fine and Gray's competing risks regression was conducted using Stata version 15 (Stata Corp, College Station, TX, USA). A two-tailed P value < 0.05 was considered statistically significant.

RESULTS

Patient Selections and Baseline Characteristics

A total of 131,306 female breast cancer patients without CT or RT between 2004 and 2015 were included in this study, of whom the tumor resection cohort included 117,012 (89.1%) patients and the no resection cohort included 14,294 (10.9%) patients. After further selection, the resection cohort consisted of 106,326 breast cancer patients.

Compared to patients without tumor resection, patients with resection were more likely to be younger, married, white, ER-positive, PR-positive, HER2-unknown, and have lower grade, left breast cancer and have lower AJCC stage (**Supplementary Table S1**). The average follow-up time was 63.8 (range: 63.6-64.1) months among 131,306 breast cancer patients.

The CVD Risk in Breast Cancer Patients and General Population

The CVD-related SMR was significantly higher in breast cancer patients without CT or RT (SMR = 2.196, 95% CI: 2.148–2.245, P<0.001) compared to the general population. In all age strata (≥45 years old), breast cancer patients without CT or RT had a higher CVD risk than the general population at the same age (all P<0.001) (**Figure 2** and **Supplementary Table S2**).

Further, CVD-related SMRs were increased to 2.031 folds (SMR = 2.031, 95% CI: 1.983–2.079, P<0.001) and 5.425 folds (SMR = 5.425, 95% CI: 5.087–5.781, P<0.001) in breast cancer patients with tumor resection and without resection respectively,


FIGURE 2 | Cardiovascular death (CVD)-related standardized mortality ratios (SMRs) for breast cancer patients without chemotherapy or radiotherapy.

compared to the general population. In all age strata (≥45 years old), the increased extent of CVD-related SMRs **were** all higher in patients without resection compared to the patients with tumor resection (no resection SMRs: 1.603–6.500; tumor resection SMRs: 1.113–2.037) (**Figure 3** and **Supplementary Table S2**).

Propensity Score-Matched Analysis

Of the 106,326 breast cancer patients selected for internal comparisons, 97,496 (91.7%) received tumor resection and 8830 (8.3%) did not. Before PSM, the variables (age at diagnosis, race, marital status, grade, ER status, PR status, HER2 status, AJCC stage) showed imbalanced between the two groups (all *P*<0.05). After the 1:1 PSM, 17,478 patients were included in the matched cohort, and the confounding covariates became balanced between the two groups (**Table 1**). Laterality and race were not allocated in PSM, and the former was balanced but the later was imbalanced before and after PSM. However, race had no confounding effect on the results after PSM (**Table 2** and **Supplementary Table S4**).

Competing Risk Regressions in Internal Comparisons

In univariate analysis before PSM and after PSM, tumor resection, age at diagnosis, marital status, PR status, and HER2 status were correlated with CVD among breast cancer patients (**Table 2**). The breast cancer patients without tumor resection showed increased CVD risk compared to the patients with tumor resection (after PSM, unadjusted HR = 1.140, 95% CI: 1.017–1.279, *P*=0.025). To eliminate the possibility of producing false positive results, regression analysis of multivariate competing risks was performed and the tumor resection was confirmed as an independent risk factor that influences CVD both before PSM and after PSM. Adjustment for cofounding covariates (model 1: age at diagnosis, marital status, PR status and HER2 status) indicated a robust adjusted hazard ratio (HR) of no resection after PSM (in model 1, adjusted HR = 1.165, 95% CI: 1.039–1.306, *P*=0.009). After further adjustment (model 2: all covariates in the

baseline), adjusted HR did not change distinctively and the CVD risk among patients without tumor resection increased to 1.166-fold compared to patients with tumor resection (in model 2, adjusted HR = 1.166, 95% CI: 1.040–1.308, *P*=0.009) (**Table 3**, **Supplementary Table S3** and **Table S4**).

In the univariate competing-risks regression analysis (**Table 2**), the CVD risk between receptor-positive subgroup and receptor-negative subgroup was no statistic difference (all *P*>0.05). In the multivariate analysis (**Supplementary Table S4**), there was also no statistic difference between the positive status and the negative (ER status, HR = 0.980, 95% CI: 0.890–1.079, *P*=0.679; PR status, HR = 0.997, 95% CI: 0.928–1.072, *P*=0.938; HER2 status, HR = 0.905, 95% CI: 0.767–1.069, *P*=0.241).

DISCUSSION

To the best of our knowledge, this is the first population-based study focusing on CVD risk among breast cancer patients without CT or RT. We found that the CVD risk increased to 2.196-fold in breast cancer patients without CT or RT compared to the general population. Previous SEER-based studies demonstrated that overall breast cancer survivors (including those with or without CT or RT) had higher CVD risk compared to the general population (9, 10). Many previous studies revealed cancer treatment-related cardiotoxicity (28), such as that from CT (6) and RT (7). However, these studies neglected the CVD risk in breast cancer patients who opted out of CT or RT. Interestingly, we found that breast cancer patients who did not receive CT or RT also suffered higher CVD risk than the general population, suggesting that CVD risk in breast cancer patients may increase independently of cardiotoxic therapies. On the other hand, due to lack of detailed information on cardiovascular complications of SEER itself, the other cardiac causes of CVD among patients with breast cancer is unclear besides cardiotoxicity. A recent study on breast cancer related to cardiovascular risk by Greenlee et al. (29) who reported that breast cancer patients suffered from increased risk of cardiovascular related diseases such as cardiac arrest, heart failure, cardiomyopathy, venous thromboembolism and carotid disease, which may be further led to elevated CVD risk.

In accordance with the study by Pavo et al. (30) who found that myocardial damage was directly linked to cancer, and myocardial damage biomarkers were upregulated in cancer patients who did not undergo cardiotoxic therapies. Likewise, a retrospective study revealed that cancer patients without CT or RT had a higher risk of cardiac dysfunction than the age- and gender-matched controls (12). However, these studies were limited due to small sample size, whereas this study included large-scale and multicenter cases. Although cardiovascular comorbidities of the research subjects could not be taken into account in this study, the compared general population also included those with or without cardiovascular comorbidities. The comparison performed by using SMR analysis, which is widely used in similar studies (9, 11, 23) may partly balance out the effect of pre-existing cardiovascular comorbidities. Moreover, the majority of the subjects accepted surgery, which indicated that they had less possibility of having serious


FIGURE 3 | Cardiovascular death (CVD)-related standardized mortality ratios (SMRs) for breast cancer patients with and without tumor resection.

TABLE 1 | Baseline characteristics before and after propensity score matching.

Variable	Before PSM (N/%)			After PSM (N/%)		
	No resection	Tumor resection	P	No resection	Tumor resection	P
N	8830	97,496		8739	8739	
Age at diagnosis			< 0.001			0.688
45-60 years	2205 (25.0)	32,652 (33.5)		2197 (25.1)	2174 (24.9)	
> 60 years	6625 (75.0)	64,844 (66.5)		6542 (74.9)	6565 (75.1)	
Race			< 0.001			< 0.001
White	6737 (76.3)	80,127 (82.2)		6668 (76.3)	7079 (81.0)	
Non-White[a]	2093 (23.7)	17,369 (17.8)		2071 (23.7)	1660 (19.0)	
Marital status			< 0.001			0.610
Married	3014 (34.1)	49,752 (51.0)		2991 (34.2)	3023 (34.6)	
Unmarried	5816 (65.9)	47,744 (49.0)		5748 (65.8)	5716 (65.4)	
Laterality			0.173			0.193
Left	4587 (51.9)	49,909 (51.2)		4535 (51.9)	4449 (50.9)	
Right	4243 (48.1)	47,587 (48.8)		4204 (48.1)	4290 (49.1)	
Grade[b]			<0.001			0.961
Low	5940 (67.3)	73,488 (75.4)		5875 (67.2)	5878 (67.3)	
High	2890 (32.7)	24,008 (24.6)		2864 (32.8)	2861 (32.7)	
ER status			< 0.001			1.000
Positive	7504 (85.0)	85,372 (87.6)		7431 (85.0)	7431 (85.0)	
Negative	1326 (15.0)	12,124 (12.4)		1308 (15.0)	1308 (15.0)	
PR status			< 0.001			0.092
Positive	6410 (72.6)	74,900 (76.8)		6350 (72.7)	6250 (71.5)	
Negative	2420 (27.4)	22,596 (23.2)		2389 (27.3)	2489 (28.5)	
HER2 status			<0.001			0.296
Positive	868 (9.8)	4,525 (4.6)		798 (9.1)	788 (9.0)	
Negative	4979 (56.4)	46,354 (47.5)		4958 (56.7)	4870 (55.7)	
Unknown	2983 (33.8)	46,617 (47.8)		2983 (34.1)	3081 (35.3)	
AJCC stage			< 0.001			0.563
I	1958 (22.2)	58,956 (60.5)		1958 (22.4)	1908 (21.8)	
II	2455 (27.8)	31,204 (32.0)		2455 (28.1)	2505 (28.7)	
III and IV	4417 (50.0)	7336 (7.5)		4326 (49.5)	4326 (49.5)	

[a]Non-White includes Black/American Indian/Alaska Native and Asian/Pacific Islander.
[b]Low (Grade I: well differentiated and Grade II: moderately differentiated) and high (Grade III: poorly differentiated and Grade IV: undifferentiated).
ER, estrogen receptor; HER2, human epidermal receptor 2; PR, progesterone receptor; PSM, propensity score matching.

cardiovascular comorbidities. These findings highlighted the CVD risk among breast cancer survivors without CT or RT, and the importance of monitoring and preventing CVD in these survivors. We speculate that the tumor itself, not merely the cardiotoxicity of CT or RT, may increase CVD risk among chemoradiotherapy-free patients.

If the speculation that tumors can increase CVD risk is indeed tenable, a reduction of CVD risk may show among breast cancer patients who undergone tumor resection. We found that tumor-resection group had significantly decreased CVD risk compared o tumor-bearing group (tumor resection SMR: 2.031; no resection SMR: 5.425). Nevertheless, the confounding covariates should be taken into account as they may affect the therapeutic approach of choice and the CVD risk, which may cause treatment selection bias and false positive results. To control for this bias, we further utilized PSM to balance the confounding factors and performed competing risk regressions to verify the independent effect of tumor resection on CVD. After PSM, we obtained a robust result, showing that the CVD risk among patients without tumor resection increased by 1.165-fold compared to patients with tumor resection (in model 1, adjusted HR = 1.165; in model 2, adjusted HR = 1.166, both $P<0.05$). The changes in regression

coefficients of tumor resection were not obvious after PSM, which indicated that PSM was reliable to balance the basic condition of patients (31). Although we could not completely adjust for all potential confounding variables, we made the greatest efforts to verify our results. These findings should be cautiously interpreted. Our study was consistent with a previous study showing significantly decreased CVD risk for cancer survivors who underwent surgery compared with the no-surgery group (32). However, tumor resection was just a covariate in the previous study (32). The present study provides stronger evidence for the correlation between CVD risk and tumor resection. Our results further support the speculation that existing breast cancer may strongly correlate with higher CVD risk.

Interestingly, even though breast cancer patients were treated with tumor resection, they still had residual CVD risk compared to the general population (SMRs = 1.113–2.037, all $P < 0.001$). This may be attributable to the overlapping risk factors of cardiovascular diseases and breast cancer, such as chronic systemic low-grade inflammation (33), hyperlipidemia, high cholesterol intake, and genetic risk factors (34), which cannot be reversed completely by tumor resection. Further studies on the residual CVD risk among cancer patients are needed.

TABLE 2 | Univariate competing-risks regression analysis of cardiovascular death.

Variable	Before PSM		After PSM	
	HR (95% CI)	P Value	HR (95% CI)	P Value
Tumor resection				
Yes	Reference		Reference	
No dissection	1.468 (1.345-1.603)	< 0.001	1.140 (1.017-1.279)	0.025
Age at diagnosis				
45-60 years	Reference		Reference	
> 60 years	12.789 (11.236-14.556)	< 0.001	8.444 (6.270-11.374)	< 0.001
Race				
White	Reference		Reference	
Non-White[a]	0.837 (0.781-0.898)	< 0.001	0.916 (0.791-1.062)	0.245
Marital status				
Married	Reference		Reference	
Unmarried	2.616 (2.475-2.765)	< 0.001	1.934 (1.681-2.226)	< 0.001
Laterality				
Left	Reference		Reference	
Right	0.964 (0.917-1.013)	0.147	0.930 (0.828-1.044)	0.220
Grade[b]				
Low	Reference		Reference	
High	0.955 (0.903-1.010)	0.109	0.882 (0.778-1.000)	0.051
ER status				
Positive	Reference		Reference	
Negative	0.984 (0.915-1.058)	0.664	0.849 (0.714-1.010)	0.065
PR status				
Positive	Reference		Reference	
Negative	1.054 (0.996-1.115)	0.070	0.831 (0.727-0.950)	0.007
HER2 status				
Positive	Reference		Reference	
Negative	0.915 (0.778-1.077)	0.286	0.989 (0.761-1.286)	0.935
Unknown	1.265 (1.081-1.480)	0.003	1.560 (1.210-2.013)	0.001
AJCC stage				
I	Reference		Reference	
II	1.445 (1.370-1.525)	< 0.001	1.139 (0.972-1.335)	0.109
III and IV	1.444 (1.334-1.562)	< 0.001	0.869 (0.748-1.009)	0.065

[a]Non-White includes Black/American Indian/Alaska Native and Asian/Pacific Islander.
[b]Low (Grade I: well differentiated and Grade II: moderately differentiated) and high (Grade III: poorly differentiated and Grade IV: undifferentiated).
ER, estrogen receptor; HER2, human epidermal receptor 2; HR, hazard ratios; PR, progesterone receptor; PSM, propensity score matching.

As far as the impact of receptor status (ER, PR, and HER2) on CVD risk in breast cancer patients is concerned, our results showed that these three receptors had no effect on CVD risk in breast cancer patients. These results were partially consistent with the study by Weberpals, et al. (22) who found that CVD risk was not relevant to the HER2 status and hormone receptor subtypes among breast cancer patients with chemotherapy or radiotherapy. Until now, there is still no direct evidence to show the association between molecular subtypes and CVD outcomes in patients with breast cancer. These results may be affected by the potential cofounding effect of hormonal therapy and targeted therapy involved in these receptors. Further long-term studies of

TABLE 3 | Multivariate competing-risks regression analysis of cardiovascular death.

Variable	Before PSM		After PSM	
	HR (95% CI)	P Value	HR (95% CI)	P Value
Unadjusted HR				
Tumor resection	Reference		Reference	
No resection	1.468 (1.345-1.603)	< 0.001	1.140 (1.017-1.279)	0.025
Model 1[a]				
Tumor resection	Reference		Reference	
No resection	1.303 (1.191-1.427)	< 0.001	1.165 (1.039-1.306)	0.009
Model 2[b]				
Tumor resection	Reference		Reference	
No resection	1.272 (1.147-1.411)	< 0.001	1.166 (1.040-1.308)	0.009

[a]Model 1: hazard ratios (HRs) were adjusted for statistically significant factors according to univariate analysis (age at diagnosis, marital status, PR status, and HER2 status).
[b]Model 2: hazard ratios were adjusted for all factors in the baseline.
PSM, propensity score matching.

a large sample are needed to focus on the relationship between molecular subtype and CVD risk.

The mechanisms underlying higher CVD risk among breast cancer survivors without CT or RT remain obscure, but the hypothetical explanations may lie in cancer-induced CVD. On the one hand, our PSM-adjusted results support the speculation that breast cancer-bearing patients are at higher CVD risk, whereas the risk could be remarkably reduced after tumor resection. On the other hand, further supporting evidence comes from basic research reporting that tumor-induced inflammation might increase CVD risk. Breast cancer could damage the cardiovascular system of breast cancer-bearing mice by initiating systemic inflammatory reactions named neutrophil extracellular traps (NETs) (35). Cancer-induced NETs could accumulate in the heart and systemic vasculature to induce cardiac dysfunction and vascular dysfunction (13, 36, 37). NETs could also promote cancer-associated arterial thrombosis and further causing ischemic strokes (35, 38). Based on the postulation that tumor-induced inflammation may increase CVD risk, anti-inflammatory drugs should decrease CVD risk. Furthermore, clinical evidences that strengthen our hypothesis come from the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) (39, 40) which showed that anti-inflammatory drugs could reduce both cancer mortality and CVD. In addition, other contributing factors might include cancer-related hypercoagulability (41, 42), tumor metastasis to the cardiovascular system (43), oxidative stress (44) and nitric oxide-dependent endothelial impairment (45). Nevertheless, the interpretations to our data remain speculative and further study is needed to investigate the underlying mechanisms.

Strengths and Limitations

The strengths of the present study are noteworthy for its large-scale population, long-term follow-up and multicenter cases. To the best of our knowledge, this is the first study to report that breast cancer survivors without CT or RT are inflicted by increased CVD risk on the population level. Some limitations of the study should be taken into account. Firstly, this is a retrospective non-randomized study which may have selection bias for patients. Nevertheless, we used PSM to resolve this limitation as much as possible. Secondly, the data on cardiovascular risk factors, cardiovascular comorbidity, and performance status were not provided by the SEER, and we could not distinguish their effects on CVD risk in our SEER-based study. To address this issue, we used CVD-related SMR in comparing the general population with or without cardiovascular conditions and performance status. Thirdly, the SEER registries do not provide the information of hormonal treatments. Nevertheless, we adjusted the molecular subtype (ER and PR) in multivariate competing-risks analysis, which might partly reduce the effect of hormonal treatments on our results.

CONCLUSIONS

This study found that breast cancer patients free of CT or RT were at higher CVD risk, and tumor resection might be a contributing factor to decreased CVD risk in breast cancer patients. Existing breast cancer might strongly correlate with higher CVD risk. Clinical practices highlight that breast cancer patients free of CT or RT should also be targets for monitoring of CVD risk and prevention of the disease. Clinicians should start to monitor CVD risk and prevent CVD once breast cancer is diagnosed. Further studies and prospective trials are needed to verify our conclusions and to explore the underlying mechanisms.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://seer.cancer.gov/.

AUTHOR CONTRIBUTIONS

TG: Conception, study design, data collection, analysis, interpretation of results, figure design, article draft writing, article–review, and editing. HZ and JY: study design, data analysis, interpretation of results, article draft writing, article–review, and editing. WL and KW: interpretation of results and figure design. MS and WP: study design and article draft writing. YML, and YXL: article draft writing. CL: Funding acquisition, interpretation of results, project administration and supervision, article–review, and editing. All authors contributed to the article and approved the submitted version.

FUNDING

ACKNOWLEDGMENTS

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.619622/full#supplementary-material

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA: A Cancer J Clin* (2020) 70(1):7–30. doi: 10.3322/caac.21590

2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. *CA Cancer J Clin* (2016) 66(2):115–32. doi: 10.3322/caac.21338

3. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. *CA: A Cancer J Clin* (2014) 64(4):252–71. doi: 10.3322/caac.21235

4. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. *Breast Cancer Res BCR* (2011) 13(3):R64. doi: 10.1186/bcr2901

5. Bardia A, Arieas ET, Zhang Z, Defilippis A, Tarpinian K, Jeter S, et al. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. *Breast Cancer Res Treat* (2012) 131(3):907–14. doi: 10.1007/s10549-011-1843-1

6. Thavendiranathan P, Abdel-Qadir H, Fischer HD, Camacho X, Amir E, Austin PC, et al. Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study. *J Clin Oncol Off J Am Soc Clin Oncol* (2016) 34(19):2239–46. doi: 10.1200/JCO.2015.65.1505

7. Saiki H, Petersen IA, Scott CG, Bailey KR, Dunlay SM, Finley RR, et al. Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer. *Circulation* (2017) 135 (15):1388–96. doi: 10.1161/CIRCULATIONAHA.116.025434

8. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* (2017) 35(8):893–911. doi: 10.1200/JCO.2016.70.5400

9. Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. *Eur Heart J* (2019) 40(48):3889–97. doi: 10.1093/eurheartj/ehz766

10. Zaorsky NG, Churilla TM, Egleston BL, Fisher SG, Ridge JA, Horwitz EM, et al. Causes of death among cancer patients. *Ann Oncol* (2017) 28(2):400–7. doi: 10.1093/annonc/mdw604

11. Weberpals J, Jansen L, Muller OJ, Brenner H. Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study. *Eur Heart J* (2018) 39 (43):3896–903. doi: 10.1093/eurheartj/ehy167

12. Tadic M, Genger M, Baudisch A, Kelle S, Cuspidi C, Belyavskiy E, et al. Left Ventricular Strain in Chemotherapy-Naive and Radiotherapy-Naive Patients With Cancer. *Can J Cardiol* (2018) 34(3):281–7. doi: 10.1016/j.cjca.2017.11.018

13. Cedervall J, Zhang Y, Huang H, Zhang L, Femel J, Dimberg A, et al. Neutrophil Extracellular Traps Accumulate in Peripheral Blood Vessels and Compromise Organ Function in Tumor-Bearing Animals. *Cancer Res* (2015) 75(13):2653–62. doi: 10.1158/0008-5472.CAN-14-3299

14. Harbeck N, Gnant M. Breast cancer. *Lancet (London England)* (2017) 389 (10074):1134–50. doi: 10.1016/S0140-6736(16)31891-8

15. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. *Lancet (London England)* (2013) 381(9880):1827–34. doi: 10.1016/S0140-6736(13)60140-3

16. Khosrow-Khavar F, Filion KB, Al-Qurashi S, Torabi N, Bouganim N, Suissa S, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. *Ann Oncol* (2017) 28(3):487–96. doi: 10.1093/annonc/mdw673

17. Matthews A, Stanway S, Farmer RE, Strongman H, Thomas S, Lyon AR, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. *BMJ (Clin Res ed)* (2018) 363:k3845. doi: 10.1136/bmj.k3845

18. Choi SH, Kim KE, Park Y, Ju YW, Jung JG, Lee ES, et al. Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data. *Breast (Edinburgh Scotland)* (2020) 54:25–30. doi: 10.1016/j.breast.2020.08.003

19. Khosrow-Khavar F, Filion KB, Bouganim N, Suissa S, Azoulay L. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study. *Circulation* (2020) 141(7):549–59. doi: 10.1161/CIRCULATIONAHA.119.044750

20. Bundred NJ. The effects of aromatase inhibitors on lipids and thrombosis. *Br J Cancer* (2005) 93Suppl 1(Suppl 1):S23–7. doi: 10.1038/sj.bjc.6602692

21. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. *Circulation* (2018) 137(8):e30–66. doi: 10.1161/CIR.0000000000000556

22. Weberpals J, Jansen L, Müller OJ, Brenner H. Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study. *Eur Heart J* (2018) 39 (43):3896–903. doi: 10.1093/eurheartj/ehy167

23. Fung C, Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR, Travis LB. Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. *J Clin Oncol Off J Am Soc Clin Oncol* (2015) 33(28):3105–15. doi: 10.1200/JCO.2014.60.3654

24. Breslow NE, Day NE. *Statistical methods in cancer research. Volume II–The design and analysis of cohort studies.* New York: Oxford University Press (1987).

25. Altman DG, Bland JM. How to obtain the P value from a confidence interval. *BMJ (Clin Res ed)* (2011) 343:d2304. doi: 10.1136/bmj.d2304

26. Hulley SB, Cummings RC, Browner WS, Grady DG, Newman TB. *Designing Clinical Research (Forth Edition)*. Philadelphia: Lippincott Williams & Wilkins (2013).

27. Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, et al. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. *JAMA Oncol* (2018) 4(5):e175230. doi: 10.1001/jamaoncol.2017.5230

28. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, et al. Cardiovascular Health of Patients With Cancer and Cancer Survivors. *J Am Coll Cardiol* (2015) 65(25):2739–46. doi: 10.1016/j.jacc.2015.04.059

29. Greenlee H, Iribarren C, Neugebauer R, Rana JS, Nguyenhuynh M, Cheng R, et al. Risk of cardiovascular disease in women with and without a history of breast cancer: The Pathways Heart Study. *J Clin Oncol* (2020) 38(15 suppl):12016. doi: 10.1200/JCO.2020.38.15_suppl.12016

30. Pavo N, Raderer M, Hulsmann M, Neuhold S, Adlbrecht C, Strunk G, et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. *Heart* (2015) 101(23):1874–80. doi: 10.1136/heartjnl-2015-307848

31. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. *N Engl J Med* (2000) 343(25):1826–32. doi: 10.1056/NEJM200012213432501

32. Abdel-Rahman O. Risk of cardiac death among cancer survivors in the United States: a SEER database analysis. *Expert Rev Anticancer Ther* (2017) 17 (9):873–8. doi: 10.1080/14737140.2017.1344099

33. Van't Klooster CC, Ridker PM, Hjortnaes J, van der Graaf Y, Asselbergs FW, Westerink J, et al. The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study. *Eur Heart J* (2019) 40(48):3901–9. doi: 10.1093/eurheartj/ehz587

34. Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, et al. Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. *Circulation* (2019) 139(13): e579–602. doi: 10.1161/CIR.0000000000000641

35. Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. *Proc Natl Acad Sci USA* (2012) 109(32):13076–81. doi: 10.1073/pnas.1200419109

36. Cedervall J, Dimberg A, Olsson A-K. Tumor-induced neutrophil extracellular traps-drivers of systemic inflammation and vascular dysfunction. *Oncoimmunology* (2015) 5(3):e1098803–e. doi: 10.1080/2162402X.2015.1098803

37. Cedervall J, Dimberg A, Olsson AK. Tumor-Induced Local and Systemic Impact on Blood Vessel Function. *Mediators Inflamm* (2015) 2015:418290. doi: 10.1155/2015/418290

38. Grazioli S, Paciaroni M, Agnelli G, Acciarresi M, Alberti A, D'Amore C, et al. Cancer-associated ischemic stroke: A retrospective multicentre cohort study. *Thromb Res* (2018) 165:33–7. doi: 10.1016/j.thromres.2018.03.011

39. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med* (2017) 377(12):1119–31. doi: 10.1056/NEJMoa1707914

40. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet* (2017) 390(10105):1833–42. doi: 10.1016/S0140-6736(17)32247-X

41. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. *Blood* (2007) 110(6):1723–9. doi: 10.1182/blood-2006-10-053736

42. Schwarzbach CJ, Schaefer A, Ebert A, Held V, Bolognese M, Kablau M, et al. Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology. *Stroke* (2012) 43(11):3029–34. doi: 10.1161/STROKEAHA.112.658625

43. Cedervall J, Zhang Y, Olsson AK. Tumor-Induced NETosis as a Risk Factor for Metastasis and Organ Failure. *Cancer Res* (2016) 76(15):4311–5. doi: 10.1158/0008-5472.CAN-15-3051

44. Dalaklioglu S, Tasatargil A, Kale S, Tanriover G, Dilmac S, Erin N. Metastatic breast carcinoma induces vascular endothelial dysfunction in Balb-c mice: Role of the tumor necrosis factor-alpha and NADPH oxidase. *Vascul Pharmacol* (2013) 59(3-4):103–11. doi: 10.1016/j.vph.2013.07.008

45. Buczek E, Denslow A, Mateuszuk L, Proniewski B, Wojcik T, Sitek B, et al. Alterations in NO- and PGI2- dependent function in aorta in the orthotopic murine model of metastatic 4T1 breast cancer: relationship with pulmonary endothelial dysfunction and systemic inflammation. *BMC Cancer* (2018) 18 (1):582–97. doi: 10.1186/s12885-018-4445-z